title: Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
abstract: To explore whether the complement factor H (CFH) polymorphism rs1061170/Y402H is associated with responsiveness to antivascular endothelial growth factor (VEGF) agents in age-related macular degeneration (AMD). We reviewed the English literature to examine the association between the polymorphism rs1061170/Y402H of the CFH gene and responsiveness to treatment with anti-VEGF drugs in AMD patients. A meta-analysis of eligible studies was also performed. Pooled odds ratios (ORs) and 95% CIs were estimated using Stata V.12.0. Statistical heterogeneity was measured using Q-statistic testing. Fourteen relevant studies including a total of 2963 AMD patients were eligible. In AMD patients without a treatment history, individuals carrying the rs1061170/Y402H TT genotype were more likely to achieve a better outcome (OR = 1.932, 95% CI = 1.125-3.317, p = 0.017) than those carrying the CC genotype. The polymorphism rs1061170/Y402H might be a genetic predictor of treatment response to anti-VEGF therapy in AMD patients. Further prospective research including a larger number of patients is needed to validate this finding.
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Hong
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Chen-Ying
authors.initials: CY
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Shu-Qun
authors.initials: SQ
authors.lastname: Wang
authors.affiliation: Department of Ophthalmology, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Tong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D017242:Complement Factor H / Q000235:genetics; D005838:Genotype; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D000069579:Ranibizumab / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; C493495:CFH protein, human; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D017242:Complement Factor H; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab
keywords: age-related macular degeneration; complement factor H; pharmacogenetics; polymorphism; vascular endothelial growth factor